{'fraction_non_alphanumeric': 0.03815261044176707, 'fraction_numerical': 0.06827309236947791, 'mean_word_length': 4.727969348659004, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Epidemiology of respiratory syncytial virus across five influenza seasons among adults and children one year of age and older - Washington State, 2011/12 - 2015/16.

BACKGROUND
Vaccines and novel prophylactics against respiratory syncytial virus (RSV) are in development. To provide a baseline for evaluating these interventions, we characterized the incidence and molecular epidemiology of RSV in persons aged ≥1 year.


METHODS
We identified patients with medically-attended acute respiratory illness (MAARI) from the 2011/12 through 2015/16 influenza seasons among members of Kaiser Permanente Washington. We estimated the cumulative incidence of MAARI for laboratory-confirmed RSV or influenza infection.


RESULTS
Annual cohorts ranged from 82,266 to 162,633 individuals, of whom 14% were children aged 1 to 17 years. Cumulative incidence of RSV each season ranged from 14 per 1,000 population (95% confidence interval [CI], 12-16) to 22 per 1,000 (95% CI, 19-25). Incidence of RSV was greater than influenza in children aged 12-23 months and 2-4 years; incidence of influenza was greater in other age groups. RSV subtype A dominated in 2011/12, 2012/13, and 2015/16, with ON1 being the most common genotype. RSV subtype B dominated in 2013/14 and 2014/15, primarily of the BA genotype.


CONCLUSIONS
The burden of RSV is comparable to that of influenza across the life course. These results provide a baseline for evaluating the impact of new RSV interventions on the epidemiology of RSV.